Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376916 · ClinicalTrials.gov registry record · Phase 3
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
A Phase 3 study of Atrial Fibrillation and Tachycardia Atrial, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
- 1
- Study location
NCT06376916 is a Phase 3 study of Atrial Fibrillation and Tachycardia Atrial that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 153 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06376916, a Phase 3 study of Atrial Fibrillation and Tachycardia Atrial, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Magnesium Sulfate 2 G
- DRUG Magnesium Sulfate 4 G
Study Locations (1)
Illinois
- Advocate Christ Medical Center Emergency Department (ACMC ED) - Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06376916
The ClinicalTrials.gov registry entry for NCT06376916 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.
NCT06376916 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06376916 about?
NCT06376916 is a clinical study titled "Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR". The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
What is the current status of trial NCT06376916?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2024-10-07. Estimated completion is 2026-12.
What conditions does trial NCT06376916 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Tachycardia Atrial, Atrial Flutter With Rapid Ventricular Response.
What interventions are being tested in trial NCT06376916?
The interventions under investigation include: Saline (DRUG), Magnesium Sulfate 2 G (DRUG), Magnesium Sulfate 4 G (DRUG).
Who is sponsoring clinical trial NCT06376916?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376916 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.